How much cash does Design Therapeutics, Inc. generate?

Design Therapeutics, Inc. (DSGN) generated -$54.0M in operating cash flow over the trailing twelve months.

What is Design Therapeutics, Inc.'s free cash flow?

After $121.0K of capital expenditures, Design Therapeutics, Inc.'s free cash flow was -$54.1M over the trailing twelve months, down 13.5% year over year.

Where does Design Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Design Therapeutics, Inc. DSGN Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$69.71M-24.0%	-$69.79M-40.7%	-$67.45M-41.2%	-$63.49M-25.6%	-$56.2M+4.2%
Depreciation and amortization	$620K+1.3%	$622K+4.4%	$615K+5.1%	$613K+7.7%	$612K+11.1%
Stock-based compensation	$14.93M+11.2%	$14.55M+11.3%	$14.59M+18.3%	$14.11M+13.6%	$13.43M+4.5%
Change in accounts payable	$2.28M—	$4.49M—	——	——	——
Change in other assets	——	——	——	——	$770K—
Net cash from operating activities	-$54M-13.8%	-$54.36M-26.1%	-$52.25M-13.5%	-$50.64M+0.8%	-$47.46M+11.4%
Capital expenditures	$121K—	$193K—	——	——	——
Purchases of investments	$257.82M-4.9%	$291.78M+26.8%	$268.53M+11.9%	$256.97M+12.7%	$271.06M+14.5%
Proceeds from maturities/sales of investments	$265.4M-12.3%	$314.89M+14.7%	$305.02M+5.9%	$281.1M-5.4%	$302.49M+4.1%
Net cash from investing activities	——	——	$36.33M—	——	——
Proceeds from issuance of common stock	$44.75M+223,870%	$24.85M—	$33K-92.3%	-$3K-101%	-$20K—
Net cash from financing activities	$45.65M+8,747%	$25.74M+4,917%	$684K-8.9%	$648K-15.1%	$516K—
Net increase (decrease) in cash	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$2.34M-57.7%	$3.25M-47.5%	$4.18M-36.6%	$4.87M-28.9%	$5.53M-17.2%
Depreciation	$620K+1.3%	$622K+4.4%	$615K+5.1%	$613K+7.7%	$612K+11.1%
Increase (Decrease) in Accounts Payable and Other Operating Liabilities	$2.28M—	$4.49M—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	$770K—
Non Cash Lease Expense Income	$52K—	-$21K—	——	——	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$265.4M-12.3%	$314.89M+14.7%	$305.02M+5.9%	$281.1M-5.4%	$302.49M+4.1%
Accrued payables for capital expenditures	——	——	——	——	——
Issuance Costs Included In Accrued Expenses	——	$17K—	$12.75K—	$8.5K—	$4.25K—
Free cash flow	-$54.12M-13.5%	-$54.55M-25.6%	-$52.41M-12.9%	-$50.78M+1.3%	-$47.67M+11.6%
Free cash flow	-$54.12M-13.5%	-$54.55M-25.6%	-$52.41M-12.9%	-$50.78M+1.3%	-$47.67M+11.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Design Therapeutics, Inc. generate?: Design Therapeutics, Inc. (DSGN) generated -$54.0M in operating cash flow over the trailing twelve months.
What is Design Therapeutics, Inc.'s free cash flow?: After $121.0K of capital expenditures, Design Therapeutics, Inc.'s free cash flow was -$54.1M over the trailing twelve months, down 13.5% year over year.
Where does Design Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.